{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:06:36Z","timestamp":1781251596880,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40265-022-01833-w","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T11:02:57Z","timestamp":1674039777000},"page":"195-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6781-7424","authenticated-orcid":false,"given":"Daniele","family":"Masarone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Kittleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Pollesello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Tedford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pacileo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"1833_CR1","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.mayocp.2020.04.039","volume":"95","author":"SA Mandras","year":"2020","unstructured":"Mandras SA, Mehta HS, Vaidya A. Pulmonary hypertension: a brief guide for clinicians. Mayo Clin Proc. 2020;95:1978\u201388.","journal-title":"Mayo Clin Proc"},{"key":"1833_CR2","doi-asserted-by":"publisher","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, R\u00e5degran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S. ESC\/ERS Scientific Document Group. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u20133731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237. PMID: 36017548.","DOI":"10.1093\/eurheartj\/ehac237"},{"key":"1833_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101236","volume":"29","author":"A Hajra","year":"2022","unstructured":"Hajra A, Safiriyu I, Balasubramanian P, Gupta R, Chowdhury S, Prasad AJ, et al. Recent advances and future prospects of treatment of pulmonary hypertension. Curr Probl Cardiol. 2022;29: 101236.","journal-title":"Curr Probl Cardiol"},{"key":"1833_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jama.2022.4402","volume":"327","author":"NF Ruopp","year":"2022","unstructured":"Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022;327:1379\u201391.","journal-title":"JAMA"},{"key":"1833_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/MCP.0000000000000891","volume":"28","author":"JLW Kennedy","year":"2022","unstructured":"Kennedy JLW, Mihalek AD. Update in approaches to pulmonary hypertension because of left heart disease. Curr Opin Pulm Med. 2022;28:337\u201342.","journal-title":"Curr Opin Pulm Med"},{"key":"1833_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2013.10.036","volume":"62","author":"W Seeger","year":"2013","unstructured":"Seeger W, Adir Y, Barber\u00e0 JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62:109\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"1833_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/diagnostics12020235","volume":"12","author":"B Ruaro","year":"2022","unstructured":"Ruaro B, Baratella E, Caforio G, Confalonieri P, Wade B, Marrocchio C, et al. Chronic thromboembolic pulmonary hypertension: an update. Diagnostics (Basel). 2022;12:235\u201346.","journal-title":"Diagnostics (Basel)."},{"key":"1833_CR8","first-page":"435","volume":"38","author":"CH Hsu","year":"2022","unstructured":"Hsu CH, Huang WC, Chang WT. Future perspectives of pulmonary hypertension treatment. Acta Cardiol Sin. 2022;38:435\u201342.","journal-title":"Acta Cardiol Sin."},{"key":"1833_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.hfc.2021.05.004","volume":"17","author":"D Masarone","year":"2021","unstructured":"Masarone D, Melillo E, Gravino R, Errigo V, Martucci ML, Caiazzo A, et al. Inotropes in patients with advanced heart failure: not only palliative care. Heart Fail Clin. 2021;17:587\u201398.","journal-title":"Heart Fail Clin"},{"key":"1833_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.15420\/cfr.2019.01.R1","volume":"5","author":"P Agostoni","year":"2019","unstructured":"Agostoni P, Farmakis DT, Garc\u00eda-Pinilla JM, Harjola VP, Karason K, von Lewinski D, et al. Haemodynamic balance in acute and advanced heart failure: an expert perspective on the role of levosimendan. Card Fail Rev. 2019;5:155\u201361.","journal-title":"Card Fail Rev"},{"key":"1833_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jchf.2021.01.015","volume":"9","author":"D Burkhoff","year":"2021","unstructured":"Burkhoff D, Borlaug BA, Shah SJ, et al. Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP Trial. JACC Heart Fail. 2021;9:360\u201370.","journal-title":"JACC Heart Fail."},{"key":"1833_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ijcard.2016.07.202","volume":"222","author":"D Farmakis","year":"2016","unstructured":"Farmakis D, Alvarez J, Gal TB, et al. Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol. 2016;222:303\u201312.","journal-title":"Int J Cardiol"},{"key":"1833_CR13","first-page":"1","volume":"8","author":"MS Hansen","year":"2018","unstructured":"Hansen MS, Andersen A, Nielsen-Kudsk JE. Levosimendan in pulmonary hypertension and right heart failure. Pulm Circ. 2018;8:1\u20137.","journal-title":"Pulm Circ."},{"key":"1833_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.15420\/cfr.2020.03","volume":"6","author":"Z Papp","year":"2020","unstructured":"Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use. Card Fail Rev. 2020;6:19\u201326.","journal-title":"Card Fail Rev"},{"key":"1833_CR15","first-page":"9","volume":"2","author":"JGF Cleland","year":"2004","unstructured":"Cleland JGF, Nikitin N, James M. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. Cardiovasc Ther. 2004;2:9\u201319.","journal-title":"Cardiovasc Ther"},{"key":"1833_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/FJC.0b013e31819c9a17","volume":"53","author":"MS Nieminen","year":"2009","unstructured":"Nieminen MS, Pollesello P, Vajda G, Papp Z. Effects of levosimendan on the energy balance: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2009;53:302\u201310.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1833_CR17","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/aas.13170","volume":"62","author":"M Fredholm","year":"2018","unstructured":"Fredholm M, J\u00f6rgensen K, Houltz E, Ricksten SE. Inotropic and lusitropic effects of levosimendan and milrinone assessed by strain echocardiography: a randomised trial. Acta Anaesthesiol Scand. 2018;62:1246\u201354.","journal-title":"Acta Anaesthesiol Scand"},{"key":"1833_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1254\/jphs.CP0060010","volume":"104","author":"O Yildiz","year":"2007","unstructured":"Yildiz O. Vasodilating mechanisms of levosimendan: involvement of K+ channels. J Pharmacol Sci. 2007;104:1\u20135.","journal-title":"J Pharmacol Sci"},{"key":"1833_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/jcpt.12067","volume":"38","author":"A Pathak","year":"2013","unstructured":"Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Ther. 2013;38:341\u20139.","journal-title":"J Clin Pharm Ther"},{"key":"1833_CR20","doi-asserted-by":"crossref","unstructured":"Burkhoff D, Rich S, Pollesello P, Papp Z. Levosimendan-induced venodilation is mediated by opening of potassium channels. 365 ESC Heart Fail. 2021;8:4454\u201364.","DOI":"10.1002\/ehf2.13669"},{"key":"1833_CR21","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1007\/s00134-011-2254-9","volume":"37","author":"M Revermann","year":"2011","unstructured":"Revermann M, Schloss M, Mieth A, Babelova A, Schr\u00f6der K, Neofitidou S, et al. Levosimendan attenuates pulmonary vascular remodeling. Intensive Care Med. 2011;37:1368\u201377.","journal-title":"Intensive Care Med"},{"key":"1833_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ejps.2007.08.003","volume":"32","author":"J Puttonen","year":"2007","unstructured":"Puttonen J, Laine T, Ramela M, et al. Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men. Eur J Pharm Sci. 2007;32:271\u20137.","journal-title":"Eur J Pharm Sci"},{"key":"1833_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejheart.2006.04.012","volume":"9","author":"J Lilleberg","year":"2007","unstructured":"Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail. 2007;9:75\u201382.","journal-title":"Eur J Heart Fail"},{"key":"1833_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00003088-200746030-00004","volume":"46","author":"J Puttonen","year":"2007","unstructured":"Puttonen J, Kantele S, Kivikko M, et al. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet. 2007;46:235\u201346.","journal-title":"Clin Pharmacokinet"},{"key":"1833_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0091270007313390","volume":"48","author":"J Puttonen","year":"2008","unstructured":"Puttonen J, Kantele S, Ruck A, et al. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment. J Clin Pharmacol. 2008;48:445\u201354.","journal-title":"J Clin Pharmacol"},{"key":"1833_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10557-018-6838-2","volume":"32","author":"S Bouchez","year":"2018","unstructured":"Bouchez S, Fedele F, Giannakoulas G, Gustafsson F, Harjola VP, Karason K, et al. Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application. Cardiovasc Drugs Ther. 2018;32:617\u201324.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1833_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/00005344-199506261-00010","volume":"26","author":"L Lehtonen","year":"1995","unstructured":"Lehtonen L, Mills-Owens P, Akkila J. Safety of levosimendan and other calcium sensitizers. J Cardiovasc Pharmacol. 1995;26:70\u20136.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1833_CR28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.repc.2014.05.009","volume":"33","author":"N Moreno","year":"2014","unstructured":"Moreno N, Tavares-Silva M, Louren\u00e7o AP, Oliveira-Pinto J, Henriques-Coelho T, Leite-Moreira AF. Levosimendan: the current situation and new prospects. Rev Port Cardiol. 2014;33:795\u2013800.","journal-title":"Rev Port Cardiol"},{"key":"1833_CR29","first-page":"143","volume":"28","author":"J Silva-Cardoso","year":"2009","unstructured":"Silva-Cardoso J, Ferreira J, Oliveira-Soares A, Martins-de-Campos J, Fonseca C, Lousada N, PORTLAND Investigators, et al. Effectiveness and safety of levosimendan in clinical practice. Rev Port Cardiol. 2009;28:143\u201354.","journal-title":"Rev Port Cardiol"},{"key":"1833_CR30","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"A Mebazaa","year":"2007","unstructured":"Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883\u201391.","journal-title":"JAMA"},{"key":"1833_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233176","volume":"15","author":"AD Rieg","year":"2020","unstructured":"Rieg AD, Suleiman S, B\u00fcnting NA, Verjans E, Spillner J, Schn\u00f6ring H, et al. Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels. PLoS ONE. 2020;15: e0233176.","journal-title":"PLoS ONE"},{"key":"1833_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1086\/677366","volume":"4","author":"MD Vildbrad","year":"2014","unstructured":"Vildbrad MD, Andersen A, Holmboe S, Ringgaard S, Nielsen JM, Nielsen-Kudsk JE. Acute effects of levosimendan in experimental models of right ventricular hypertrophy and failure. Pulm Circ. 2014;4:511\u20139.","journal-title":"Pulm Circ."},{"key":"1833_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/FJC.0000000000000508","volume":"70","author":"MS Hansen","year":"2017","unstructured":"Hansen MS, Andersen A, Holmboe S, Schultz JG, Ringgaard S, Simonsen U, et al. Levosimendan prevents and reverts right ventricular failure in experimental pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2017;70:232\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1833_CR34","first-page":"1","volume":"8","author":"MS Hansen","year":"2018","unstructured":"Hansen MS, Andersen A, Tolbod LP, Hansson NH, Nielsen R, Vonk-Noordegraaf A, et al. Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure. Pulm Circ. 2018;8:1\u201312.","journal-title":"Pulm Circ."},{"key":"1833_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/0091270008325150","volume":"49","author":"FX Kleber","year":"2009","unstructured":"Kleber FX, Bollmann T, Borst MM, et al. Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol. 2009;49:109\u201315.","journal-title":"J Clin Pharmacol"},{"key":"1833_CR36","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1111\/crj.12699","volume":"12","author":"R Jiang","year":"2018","unstructured":"Jiang R, Zhao QH, Wu WH, et al. Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension. Clin Respir J. 2018;12:1518\u201325.","journal-title":"Clin Respir J"},{"key":"1833_CR37","doi-asserted-by":"publisher","first-page":"778620","DOI":"10.3389\/fmed.2022.778620","volume":"9","author":"C Qu","year":"2022","unstructured":"Qu C, Feng W, Zhao Q, et al. Effect of levosimendan on acute decompensated right heart failure in patients with connective tissue disease-associated pulmonary arterial hypertension. Front Med (Lausanne). 2022;9:778620\u20139.","journal-title":"Front Med (Lausanne)."},{"key":"1833_CR38","doi-asserted-by":"publisher","first-page":"1801897","DOI":"10.1183\/13993003.01897-2018","volume":"53","author":"JL Vachi\u00e9ry","year":"2019","unstructured":"Vachi\u00e9ry JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53:1801897.","journal-title":"Eur Respir J"},{"key":"1833_CR39","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1161\/01.CIR.102.18.2222","volume":"102","author":"MT Slawsky","year":"2000","unstructured":"Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure Study Investigators. Circulation. 2000;102:2222\u20137.","journal-title":"Circulation"},{"issue":"11","key":"1833_CR40","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.amjcard.2006.06.052","volume":"98","author":"JT Parissis","year":"2006","unstructured":"Parissis JT, Paraskevaidis I, Bistola V, et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol. 2006;98(11):1489\u201392.","journal-title":"Am J Cardiol"},{"key":"1833_CR41","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1742-1241.2007.01510.x","volume":"62","author":"H Duygu","year":"2008","unstructured":"Duygu H, Ozerkan F, Zoghi M, et al. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. Int J Clin Pract. 2008;62:228\u201333.","journal-title":"Int J Clin Pract"},{"key":"1833_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/FJC.0000000000001163","volume":"79","author":"D Masarone","year":"2022","unstructured":"Masarone D, Melillo E, Errigo V, Martucci ML, Pacileo R, Pollesello P, et al. Hemodynamic effects of levosimendan in outpatients with advanced heart failure: an echocardiographic pilot study. J Cardiovasc Pharmacol. 2022;79:36\u201340.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"11","key":"1833_CR43","doi-asserted-by":"publisher","first-page":"24097","DOI":"10.1038\/s41598-021-03317-5","volume":"16","author":"Y Hu","year":"2021","unstructured":"Hu Y, Wei Z, Zhang C, Lu C, Zeng Z. The effect of levosimendan on right ventricular function in patients with heart dysfunction: a systematic review and meta-analysis. Sci Rep. 2021;16(11):24097\u2013105.","journal-title":"Sci Rep"},{"key":"1833_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1378\/chest.13-1900","volume":"146","author":"ME Pugh","year":"2014","unstructured":"Pugh ME, Sivarajan L, Wang L, Robbins IM, Newman JH, Hemnes AR. Causes of pulmonary hypertension in the elderly. Chest. 2014;146:159\u201366.","journal-title":"Chest"},{"key":"1833_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1164\/rccm.200805-732OC","volume":"179","author":"HW Van Hees","year":"2009","unstructured":"Van Hees HW, Dekhuijzen PN, Heunks LM. Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179:41\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1833_CR46","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nrd2466","volume":"7","author":"JO Lundberg","year":"2008","unstructured":"Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008;7:156\u201367.","journal-title":"Nat Rev Drug Discov"},{"key":"1833_CR47","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1097\/01.CCM.0000230244.17174.4F","volume":"34","author":"A Morelli","year":"2006","unstructured":"Morelli A, Teboul JL, Maggiore SM, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med. 2006;34:2287\u201393.","journal-title":"Crit Care Med"},{"key":"1833_CR48","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1183\/09031936.00137614","volume":"45","author":"HT Robertson","year":"2015","unstructured":"Robertson HT. Dead space: the physiology of wasted ventilation. Eur Respir J. 2015;45:1704\u201316.","journal-title":"Eur Respir J"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01833-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01833-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01833-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T07:30:13Z","timestamp":1676446213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01833-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1833"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01833-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"20 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ryan J. Tedford was a funded site principal investigator for the HELP study. Piero Polesello is a full-time employee of Orion Pharma, where levosimendan was discovered and developed. Daniele Masarone, Michelle Kittleson, and Giuseppe Pacileo have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"DM and GP: Conceptualization. DM and GP:  Writing - Original Draft. MK, RT and PP: Writing - Review & Editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}